UNSPSC 51263115: Bupranolol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C14H22ClNO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 858YGI5PIT, chemically known as 2-propanol, 1-(tert-butylamino)-3-((6-chloro-m-tolyl)oxy)- (8ci) but generally known as bupranolol, which bears US NIH Compound Identifier 2475. Bupranolol most often comes in base and hydrochloride forms. European Medicines Agency schedules Bupranolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05984MIG.

UNSPSC 51263115 Bupranolol (Commodity) does not align with the recent state and local activity posted under this code. Seminole County, Florida's IFB 60459723LAS, posted June 30, 2026 with a response deadline of July 26, 2023, solicits 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually—neither of which are bupranolol. The mismatch suggests either a cataloging error or that the code is being misapplied to opioid-reversal and drug-disposal equipment that falls outside the pharmaceutical-ingredient scope the UNSPSC number nominally covers. State and local procurement databases occasionally tag opportunities with codes that do not match the goods actually being purchased, and this appears to be an instance of that divergence.

The single recent opportunity in the dataset provides no meaningful signal about what state and local governments actually buy under UNSPSC 51263115. Absent additional opportunities correctly tagged to bupranolol procurement, no reliable characterization of issuing-body mix, geographic spread, or representative work patterns emerges. The code shows little relevant recent activity.